Jefferies Starts Dyax Corp. (DYAX) at Buy
Tweet Send to a FriendGet Alerts DYAX Hot Sheet
Price: $2.52 --0%
Rating Summary:
3 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 6
Rating Summary:
3 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 6
Trade DYAX Now!
Jefferies initiates coverage on Dyax Corp. (NASDAQ: DYAX) with a Buy. PT $6.00.
The firm comments, "With its wholly owned marketed orphan drug asset and a widely partnered tech platform, DYAX is an attractive small-cap biotech play. While long-term U.S. Kalbitor sales grow steadily, royalties from potential Japan Kalbitor sales and U.S. ramucirumab sales across an increasing number of cancer indications provide additional legs of growth near/mid-term, likely driving significant value not factored into the current share price."
For an analyst ratings summary and ratings history on Dyax Corp. click here. For more ratings news on Dyax Corp. click here.
Shares of Dyax Corp. closed at $3.27 yesterday, with a 52 week range of $1.32-$3.74.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The firm comments, "With its wholly owned marketed orphan drug asset and a widely partnered tech platform, DYAX is an attractive small-cap biotech play. While long-term U.S. Kalbitor sales grow steadily, royalties from potential Japan Kalbitor sales and U.S. ramucirumab sales across an increasing number of cancer indications provide additional legs of growth near/mid-term, likely driving significant value not factored into the current share price."
For an analyst ratings summary and ratings history on Dyax Corp. click here. For more ratings news on Dyax Corp. click here.
Shares of Dyax Corp. closed at $3.27 yesterday, with a 52 week range of $1.32-$3.74.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Michael Kors (KORS) Under-Appreciated; Canaccord Genuity Starts at Buy
- Piper Jaffray Starts JAKKS Pacific (JAKK) at Neutral
- UPDATE: Wedbush Downgrades XenoPort (XNPT) to Neutral
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageRelated Entities
Jefferies & Co
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
